A live avirulent mutant Legionella pneumophila vaccine induces protective immunity against lethal aerosol challenge - PubMed (original) (raw)

A live avirulent mutant Legionella pneumophila vaccine induces protective immunity against lethal aerosol challenge

S J Blander et al. J Clin Invest. 1989 Mar.

Abstract

We have examined the capacity of a live avirulent mutant form of the intracellular bacterial pathogen Legionella pneumophila to induce immune responses and protective immunity in guinea pigs. The mutant L. pneumophila is nonlethal to guinea pigs and does not revert to virulence with passage through guinea pigs. In contrast, exposure of guinea pigs to aerosols containing wild-type L. pneumophila induces a pneumonic illness that clinically and pathologically resembles Legionnaires' disease in humans. Guinea pigs immunized by aerosol exposure to mutant L. pneumophila developed a strong humoral immune response to wild-type L. pneumophila antigens with reciprocal antibody titers of 32-512 (median 256) by the indirect fluorescent antibody assay, compared with titers of less than 2 for control (sham immunized) guinea pigs. Mutant immunized but not control guinea pigs also developed strong cell-mediated immune responses to wild-type L. pneumophila antigens, as demonstrated in assays of cutaneous delayed-type hypersensitivity and in vitro splenic lymphocyte proliferation. Mutant immunized guinea pigs developed strong protective immunity to lethal aerosol challenge with wild-type L. pneumophila. In four independent experiments 40-83% of mutant immunized guinea pigs survived compared with 0% of control guinea pigs. Overall, 13 of 21 (62%) mutant immunized guinea pigs survived compared with 0 of 21 (0%) control guinea pigs (P = 0.00002, Fisher's exact test, two-tailed). Mutant immunization induced protection comparable to wild-type immunization in these studies; 8 of 14 (57%) guinea pigs immunized by wild-type L. pneumophila survived. This study demonstrates that guinea pigs immunized with a live avirulent mutant L. pneumophila vaccine (a) develop a strong humoral immune response to wild-type L. pneumophila antigens; (b) develop a strong cell-mediated immune response to wild-type L. pneumophila antigens; and (c) develop protective immunity to lethal aerosol challenge with wild-type L. pneumophila. This study demonstrates the feasibility of a vaccine against Legionnaires' disease.

PubMed Disclaimer

Cited by

Identification of a Legionella pneumophila locus required for intracellular multiplication in human macrophages.
Marra A, Blander SJ, Horwitz MA, Shuman HA. Marra A, et al. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9607-11. doi: 10.1073/pnas.89.20.9607. Proc Natl Acad Sci U S A. 1992. PMID: 1409673 Free PMC article.
Nosocomial Legionnaire's disease--a case report and review of the literature.
Woo JH, Kim SA, Park CS, Choi TY, Chang IC, Lee IS. Woo JH, et al. Korean J Intern Med. 1992 Jan;7(1):68-72. doi: 10.3904/kjim.1992.7.1.68. Korean J Intern Med. 1992. PMID: 1477034 Free PMC article. Review.
Viewing Legionella pneumophila Pathogenesis through an Immunological Lens.
Liu X, Shin S. Liu X, et al. J Mol Biol. 2019 Oct 4;431(21):4321-4344. doi: 10.1016/j.jmb.2019.07.028. Epub 2019 Jul 25. J Mol Biol. 2019. PMID: 31351897 Free PMC article. Review.

References

1. J Clin Microbiol. 1979 Mar;9(3):379-83 - PubMed
1. J Exp Med. 1987 Nov 1;166(5):1310-28 - PubMed
1. J Clin Invest. 1980 Sep;66(3):441-50 - PubMed
1. J Exp Med. 1981 Feb 1;153(2):386-97 - PubMed
1. J Exp Med. 1981 Feb 1;153(2):398-406 - PubMed

A live avirulent mutant Legionella pneumophila vaccine induces protective immunity against lethal aerosol challenge - PubMed (original) (raw)